Clinical Trials Logo

Clinical Trial Summary

Testing the effectiveness of an exercise protocol engines sensory performed through a virtual reality platform in individuals infected with HTLV-1


Clinical Trial Description

Crossover randomized clinical trial to be conducted with people having a previous diagnosis of HTLV-1, they can remain in standing position without assistance. They will be excluded from those presenting amputation of the lower limbs, pregnancy, psychiatric disorders, rheumatic or orthopedic diseases, other neurological disorders associated and those that are experiencing difficulty in understanding the assessment tools used. They will also be recruited to a comparative group, healthy individuals, matched for sex, age and education level. It will be performed three assessments, before randomization, after 10 weeks and after 20 weeks, which will be evaluated in balance, functional mobility, gait and posture. The participants infected with HTLV-1, will be divided into two groups by random distribution, a group will begin the treatment protocol with video game immediately after the first evaluation and the other after ten weeks, with the crossing of the groups . Concealment of allocation will be guaranteed to the examiners who will have no contact with the physiotherapist who will apply the exercise protocol and the team member responsible for drawing. Patients will also be instructed to maintain confidentiality of the entry in the exercise program to other patients and examiners. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02877030
Study type Interventional
Source Pedreira, Érika, M.D.
Contact
Status Completed
Phase N/A
Start date April 2, 2017
Completion date May 5, 2018

See also
  Status Clinical Trial Phase
Completed NCT01472263 - Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Phase 3
Completed NCT01651819 - Urological Physical Therapy in HTLV-1 With Urinary Symptoms N/A
Completed NCT02439918 - Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa N/A
Completed NCT00076843 - Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Phase 1